Arvaya Healthcare AGM: ₹390 cr RPT approval vote FY27

AGM scheduled via video conference on September 21

Arvaya Healthcare Limited (formerly Bijoy Hans Limited) has scheduled its 41st Annual General Meeting (AGM) for Monday, September 21, 2026 at 3:00 pm IST. The company has said the meeting will be held through video conference. The AGM agenda includes regular shareholder approvals, along with a set of special business resolutions that focus on governance and related-party dealings for FY27.

A key item is shareholder approval for material related party transactions (RPTs) aggregating to ₹390 crore for FY27. Another proposal on the agenda is the reappointment of Managing Director Kaushal Uttam Shah. The company has also placed an intellectual property acquisition proposal for shareholder approval, with a funding source linked to rights issue proceeds.

Voting window, cut-off date, and shareholder communication

Arvaya Healthcare has set September 14, 2026 as the cut-off date for determining e-voting eligibility. The e-voting window is scheduled to remain open from September 18, 2026 to September 20, 2026.

The company has also communicated AGM access details through web links. As part of this process, it dispatched letters containing the web link to the Annual Report and AGM notice to 3,092 shareholders who do not have registered email addresses. Separately, the company’s disclosures also refer to newspaper publication relating to the dispatch of the 41st AGM notice and to web links for accessing the AGM notice and annual report.

Ordinary business: FY26 accounts up for adoption

Alongside the special resolutions, the AGM includes ordinary business items. These include adoption of the audited standalone and consolidated financial statements for FY26.

For investors, these routine resolutions often serve as a checkpoint on compliance and reporting, especially when a company is simultaneously seeking shareholder approval for higher-value related-party arrangements and acquisitions. The FY26 audited statements form the baseline against which FY27 proposals and authorisations are evaluated.

Reappointment of Managing Director Kaushal Uttam Shah

One of the AGM’s special business items is the reappointment of Mr. Kaushal Uttam Shah (DIN: 02175130). The notice states he “retires by rotation,” and the reappointment is included for shareholder approval.

This resolution sits alongside broader governance proposals. In practice, such reappointment votes are closely tracked by shareholders because the same management team typically oversees execution of acquisitions, related-party arrangements, and capital deployment plans that are brought to shareholders.

Shareholders to vote on ₹390 crore related-party transactions

The largest value item in the AGM agenda is approval for entering into material RPTs with promoters, promoter group entities, and wholly owned subsidiaries for FY27. The aggregate value of the proposed transactions is ₹390 crore, and the approval is stated to remain valid until the next AGM.

The disclosed list includes multiple counterparties across promoter, promoter group, and subsidiary categories. The proposed values are presented in ₹ crore terms. Shareholder approval of these limits is relevant because the transactions are “material” and therefore require explicit authorisation under applicable governance norms.

Breakdown of proposed RPT counterparties

IP acquisition proposal: up to ₹10 crore from rights issue proceeds

The AGM notice also includes a resolution to approve acquisition of the Copyright and Intellectual Property portfolio of DEFIB Institute of Health Solutions LLP. The approval sought is for up to ₹10 crore.

As disclosed, the company intends to fund this acquisition from rights issue proceeds. The funding line is important because it links the proposal to prior or planned capital raising and signals how the company intends to deploy those proceeds.

Market snapshot: price, market cap, and identifiers

As of September 21, 2026, Arvaya Healthcare’s share price is stated as ₹110.20, with a time stamp of 09:09 IST. The market capitalisation is stated as ₹556.81 crore as on the same date. The stock symbol is 524723 on the BSE, and the ISIN is INE491D01017.

The disclosures also contain other price points from earlier dates, including ₹125.00 (up 2.38%) as on September 8, 2026 and ₹118.75 as on September 4, 2026. These data points indicate multiple reported snapshots across dates, and investors typically track them alongside corporate actions such as AGM resolutions.

Recent corporate actions around acquisitions and shareholder approvals

Beyond the AGM agenda, Arvaya Healthcare has separately disclosed a board meeting scheduled for August 26, 2026 to consider an acquisition. The target entity is Navahmedi Solution Private Limited, and the transaction structure is described as a slump sale involving acquisition of a business undertaking. The disclosure was filed with the BSE Listing Department on August 21, 2026, and the company has said it intends to fund the deal through rights issue proceeds, classifying the proposal as a related party transaction.

In another development disclosed in the same information set, shareholders have unanimously passed six resolutions via postal ballot, supporting the acquisition of Sushodha Institute of Gastroenterology Private Limited. The approvals included a preferential equity issue and related-party transactions, along with shifting the registered office to Maharashtra and regularising an executive director appointment.

Financial context: Q1FY27 turnaround in consolidated profit

Arvaya Healthcare has reported a consolidated net profit of ₹0.53 crore in Q1FY27, compared with a net loss of ₹0.25 crore in the corresponding quarter of FY26. Consolidated revenue for Q1FY27 is stated at ₹29.91 crore, with the disclosure noting it tripled year-on-year.

The same update states standalone operations remained loss-making, with a standalone net loss of ₹0.89 crore and minimal revenue. For investors, this contrast between consolidated and standalone performance is relevant when assessing the operating base that will support RPT volumes and acquisition integration.

Key dates and resolutions at a glance

Why the AGM matters for governance and capital allocation

The AGM combines standard approvals with decisions that directly shape the company’s governance guardrails for FY27. The ₹390 crore RPT limit is a key control point because it sets an authorised ceiling for transactions involving promoters, promoter group entities, and subsidiaries, and it remains valid until the next AGM.

At the same time, the IP acquisition proposal and other acquisition-related disclosures tie back to rights issue proceeds as a funding source. Taken together, these items place focus on how the company plans to deploy capital while maintaining shareholder oversight through formal approvals.

What to watch next

The immediate milestone is the outcome of shareholder voting and the AGM resolutions on September 21, 2026. Separately, the company has indicated that a board meeting was scheduled for August 26, 2026 to consider the Navahmedi Solution Private Limited acquisition, making the board’s decision another confirmed event in the recent timeline.

If approved, the RPT authorisations will run until the next AGM, and the company will have shareholder clearance for the DEFIB Institute of Health Solutions LLP IP acquisition up to ₹10 crore as disclosed.